Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients

REFERENCES

• World Health Organisation (WHO). World Health Statistics. Available at: http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf Accessed: 10 November 2008.
   Google Scholar
• GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2009. Available at http://www.goldcopd.com Accessed: 23 December 2009.
   Google Scholar
• Cazzola M., Santus P, Verga M, Mondoni M, Di Marco F, Matera MG. The functional impact of adding salmeterol to tiotropium in patients with stable COPD. Respir Med 2004; 98:1214–1221.
   PubMed Web of Science ®Google Scholar
• Brashier B, Jantikar A, Maganji M, Raghupathy A, Valsa S, Gokhale P, Mahadik P, Gogtay J, Salvi SS. Addition of formoterol to tiotropium produces better FEV1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD (Abstract). Chest 2005; 128:258s.
   Google Scholar
• Cazzola M, Noschese P, Salzillo A, De Giglio C, D’Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005; 99:524–528.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJG. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214–222.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJG. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129:509–517.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O’Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545–555.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255–262.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008a; 102:1511–1520.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102:479–487.
   PubMed Web of Science ®Google Scholar
• Tashkin D, Pearle J, Iezzoni D, Varghese ST. Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease: Findings from a randomized, placebo-controlled trial. J COPD 2009; 6:17–25.
   PubMedGoogle Scholar
• van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010; 10(7):995–1004.
   Google Scholar
• Cazzola M, Matera MG. The effective treatment of COPD: Anticholinergics and what else? Drug Disc Today: Therapeut Strateg 2006; 3(3):277–286.
   Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23(4):257–267.
   PubMed Web of Science ®Google Scholar
• Roig J, Hernando R, Mora R. Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist. The Open Respiratory Medicine Journal 2009, 3:27–30.
   PubMedGoogle Scholar
• Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007;52:833–851.
   PubMed Web of Science ®Google Scholar
• Ray NC, Alcaraz L. Muscarinic antagonist-β2–adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review Expert Opin. Ther Patents 2009;19(1):1–12.
   PubMed Web of Science ®Google Scholar
• Sarria B, Naline E, Zhang Y, Cortijo J, Molimard M, Moreau J, Therond P, Advenier C, Morcillo EJ. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol 2002; 283(5):L1125–L1132.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Omiston TM, Salpeter EE. Cardiovascular effects of β2-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309–2321.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439–1450.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulmon Pharmacol Ther 2007; 20:495–502.
   PubMed Web of Science ®Google Scholar
• Rabe KF. Anticholinergic Drugs for the Treatment of COPD Are Safe… Are They? Chest 2010; 137:1–3.
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D’Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102:1033–1044.
   PubMed Web of Science ®Google Scholar
• Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20:740–749.
   PubMed Web of Science ®Google Scholar
• Dahl RP, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65:473–479.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Once-daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol versus Tiotropium. Am J Respir Crit Care Med 2010; 182:155–162.
   PubMed Web of Science ®Google Scholar
• Khindri S, Sabo R, Harris S, Jennings S, Drollman AF. Cardiac safety of indacaterol—no clinical effect on QT in healthy subjects. Eur Respir J 2009; 34(Suppl. 53):2031.
   Google Scholar
• Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010; 23:438–444.
   PubMed Web of Science ®Google Scholar
• Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010; 104:1482–1489.
   PubMed Web of Science ®Google Scholar
• Bremmer P, Woodmarn K, Burgess C, Crane J, Purdie G, Pearce N, Beasley RA. Comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204–210.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD. Chest 2008; 133:1079–1087.
   PubMed Web of Science ®Google Scholar
• Welleck S. Testing Statistical Hypotheses of Equivalence, 1st Edition, London: Chapman and Hall, 2002.
   Google Scholar
• Ferguson G, Funck-Bretano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817–1824.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20–30.
   PubMed Web of Science ®Google Scholar